111, Inc. Forms Special Committee to Explore Strategic Options

On September 28, 2026, 111, Inc., a prominent tech-enabled healthcare platform company operating in China (NASDAQ: YI), disclosed the establishment of a special committee by its Board of Directors. This committee, which comprises three independent directors, aims to assess a preliminary and non-binding acquisition proposal that was introduced on September 16, 2026. The formation of this committee signifies a strategic move as the company navigates various potential pathways for growth and expansion.

The special committee is chaired by Mr. Jian Sun, accompanied by Mr. Nee Chuan Teo and Mr. Jun Luo. Their primary role involves a thorough evaluation of the proposal while also considering other strategic alternatives that might be beneficial for the company moving forward. The announcement has sparked interest among investors and stakeholders, at a time when the global market dynamics for healthcare are rapidly evolving.

In a cautionary note, the board has advised shareholders and interested parties not to assume any decisions have been made regarding the proposal or any alternative actions. There is also no guarantee that a definitive agreement will be reached or executed related to the transaction outlined in the proposal. As such, 111, Inc. does not commit to providing updates about the situation unless mandated by applicable laws.

This development comes as part of a broader strategy by 111 to remain competitive within the healthcare sector. The healthcare industry in China is transforming, driven by advancements in digital platforms and technologies that aim to enhance accessibility and efficiency in healthcare delivery. 111, Inc. has been at the forefront of this transformation by leveraging artificial intelligence and technology to connect various healthcare participants, ranging from consumers to pharmaceutical companies.

The company has positioned itself as a leader in the healthcare value chain through its innovative solutions that facilitate easy access to pharmaceuticals and healthcare services. Its integrated e-commerce platform and AI-based offerings are designed to improve operational efficiency within the healthcare ecosystem, addressing key challenges such as inventory management and market intelligence.

111 has emphasized the importance of embracing digital transformation, transitioning from a conventional digital business model to an AI-empowered healthcare service provider. By employing AI Agents, the company enables pharmacies and healthcare players to automate critical operational tasks, including pricing, sales analysis, and supply chain management.

As stakeholders wait for further disclosures, analysts are keenly watching to see how the establishment of the special committee will impact 111's strategic trajectory and its ability to maintain relevance in a competitive marketplace. Any firm decisions originating from this committee could substantially influence the company's operational strategy and financial outlook in the coming years.

In conclusion, 111, Inc.’s proactive approach to forming a special committee reflects a commitment to thorough evaluation and consideration of strategic options that align with the company's long-term objectives. As the healthcare market continues to adapt and evolve, 111 remains focused on optimizing its business model to deliver improved outcomes for its customers and partners.

For further inquiries about the company and its services, you can visit 111's official site or reach out through their investor relations department.